Results 141 to 150 of about 176,739 (297)

Protocol for a non-inferiority randomized controlled trial of spontaneous breathing trial in children with and without pressure support. [PDF]

Crit Care Sci
Colleti Junior J, Araujo OR, Weber KT, Santos GMVD, Silva DCBD, Volpon LC, Carlotti APCP.   +6 more
europepmc   +1 more source

Effectiveness of Topic-Based Chatbots on Mental Health Self-Care and Mental Well-Being: Randomized Controlled Trial

Alan C. Y. Tong, K.T. Wong, Wing W. T. Chung, Winnie W. S. Mak   +3 more
openalex   +1 more source

Clinically Relevant Outcome Measures in Women With Adrenoleukodystrophy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Adrenoleukodystrophy is a rare inherited peroxisomal disease caused by pathogenic variants in the ABCD1 gene located on the X chromosome. Although the most severe central nervous system and adrenal complications typically affect only men with adrenoleukodystrophy, the majority of women develop myeloneuropathy symptoms in adulthood.
Chenwei Yan, Elizabeth I. Pierpont, Amena S. Fine, Reena V. Kartha   +3 more
wiley   +1 more source

The role of probiotics and probiotic fortified products supplementation in improving nutritional outcomes in children under 5 with acute malnutrition: a systematic review and meta-analysis of randomized, controlled trials protocol. [PDF]

Syst Rev
Tikuneh AH, Bogale EK, Beyene GA, Deribew A.   +3 more
europepmc   +1 more source

Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Spinocerebellar ataxia type 3 (SCA3) is a genetically defined ataxia. The Scale for Assessment and Rating of Ataxia (SARA) is a clinician‐reported outcome that measures ataxia severity at a single time point. In its standard application, SARA fails to capture short‐term fluctuations, limiting its sensitivity in trials.
Marcus Grobe‐Einsler, Vivian Maas, Arian Taheri Amin, Jennifer Faber, Tamara Schaprian, Katharina Hill, Matthis Synofzik, Lisa H. Graf, Heike Jacobi, Manuela Lima, Ana F. Ferreira, Bart P. van de Warrenburg, Ilse H. J. Willemse, Dagmar Timmann, Andreas Thieme, Paola Giunti, Hector Garcia‐Moreno, Magda M. Santana, Jeannette Hübener‐Schmid, Elin H. Davies, Thomas Klockgether   +20 more
wiley   +1 more source

The Impact of Mobile Health Interventions on Mental Health Literacy: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

J Eval Clin Pract
Patel J, Li M, Elsahli N, Katapally TR.
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Efficacy of Janus kinase inhibitor combined with phototherapy in non-segmental vitiligo: systematic review and meta-analysis. [PDF]

Ann Med
Shuaib L, D Rai K, K Sangtiani A, Ishtiaq J, Mubeen M, Saeed A, Poudel S.   +6 more
europepmc   +1 more source

A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

Arthritis Care &Research, EarlyView.
This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases.
Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy   +5 more
wiley   +1 more source

Uncertain use of a fixed p value significance threshold in randomized clinical trials. [PDF]

Trials
Habibzadeh F.
europepmc   +1 more source